Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALEXANDER N STARODUB

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1124087135
CMS profile
6028
Location
CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$14,561.76

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $14,561.76 9

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALEXANDER N STARODUB

NPI 1124087135 · CMS profile ID 6028

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

CINCINNATI, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALEXANDER N STARODUB, NPI 1124087135, CMS profile ID 6028. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). ALEXANDER N STARODUB, NPI 1124087135, CMS profile ID 6028. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
ALEXANDER N STARODUB, NPI 1124087135, CMS profile ID 6028, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1124087135?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $14,561.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $2,520.0009/15/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891851 CMS
E.R. Squibb & Sons, L.L.C. $2,520.0008/25/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891857 CMS
E.R. Squibb & Sons, L.L.C. $2,535.0006/30/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891845 CMS
E.R. Squibb & Sons, L.L.C. $500.0006/11/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891883 CMS
E.R. Squibb & Sons, L.L.C. $1,000.0005/26/2020 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891878 CMS
E.R. Squibb & Sons, L.L.C. $360.7003/26/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891841 CMS
E.R. Squibb & Sons, L.L.C. $5,070.0002/20/2020 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891831 CMS
E.R. Squibb & Sons, L.L.C. $6.2502/11/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891819 CMS
E.R. Squibb & Sons, L.L.C. $49.8102/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727891825 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,702.59 55
PY2020 $14,561.76 9
PY2021 $6,470.00 4
PY2022 $3,527.70 20
PY2023 $6,052.49 26
PY2024 $239.67 4
PY2025 $71.50 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $181,361.55 30
PY2024 Principal investigator $286,229.93 39
PY2023 Principal investigator $372,024.13 41
PY2022 Principal investigator $106.50 1
PY2021 Principal investigator $13,750.00 5
PY2020 Principal investigator $11,421.34 16
PY2019 Principal investigator $156,760.95 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

33 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $21.40 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480645
Principal investigator 1 Incyte Corporation $52.12 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480647
Principal investigator 1 Incyte Corporation $103.60 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480649
Principal investigator 1 Incyte Corporation $61.75 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480651
Principal investigator 1 Incyte Corporation $53.50 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480653
Principal investigator 1 Incyte Corporation $171.20 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480655
Principal investigator 1 Incyte Corporation $1.25 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480657
Principal investigator 1 Incyte Corporation $15.40 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480659
Principal investigator 1 Incyte Corporation $25.70 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480661
Principal investigator 1 Incyte Corporation $85.60 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480663
Principal investigator 1 Incyte Corporation $28.94 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480665
Principal investigator 1 Incyte Corporation $21.40 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480673
Principal investigator 1 Incyte Corporation $21.40 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480675
Principal investigator 1 Incyte Corporation $171.20 11/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480677
Principal investigator 1 Incyte Corporation $25.70 10/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480639
Principal investigator 1 Incyte Corporation $24.70 10/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480641
Principal investigator 1 Incyte Corporation $21.40 10/08/2019 Non-covered Recipient Entity
PENINSULA CANCER INSTITUTE-NEWPORT NEWS
A Phase 3, Open Label, Randomized, Active Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement FIGHT 302 No dispute reported 06/30/2026 666480643
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,727.90 05/31/2019 Non-covered Recipient Entity
GOSHEN HOSPITAL ASSOCIATION
A PHASE III RANDOMIZED 3 ARM OPEN LABEL MULTICENTER STUDY OF LGX818 PLUS MEK162 AND LGX818 MONOTHERAPY COMPARED WITH VEMURAFENIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA No dispute reported 06/30/2026 640716717
Principal investigator 1 Incyte Corporation $1,000.00 03/26/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Multicenter, International, Open Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B Cell Lymphoma No dispute reported 06/30/2026 666468993
Principal investigator 1 Incyte Corporation $500.00 03/26/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Multicenter, International, Open Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B Cell Lymphoma No dispute reported 06/30/2026 666468995
Principal investigator 1 Incyte Corporation $225.00 03/26/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Multicenter, International, Open Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B Cell Lymphoma No dispute reported 06/30/2026 666468997
Principal investigator 1 Gilead Sciences, Inc. $489.00 03/25/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 676487263
Principal investigator 1 AbbVie, Inc. $89,422.59 03/13/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
M16-290 No dispute reported 06/30/2026 647578395
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 03/08/2019 Non-covered Recipient Entity
PARKVIEW RESEARCH CENTER
A Phase I,II Study to Assess the Safety and Efficacy of MK-3475 in Combination withTrametinib and Dabrafenib in Subjects with Advanced Melanoma No dispute reported 06/30/2026 691320115
Principal investigator 1 Gilead Sciences, Inc. $2,632.00 02/20/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 676487257
Principal investigator 1 Incyte Corporation $49,604.00 02/14/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666468989
Principal investigator 1 Gilead Sciences, Inc. $2,000.00 01/30/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 676487251
Principal investigator 1 Gilead Sciences, Inc. $324.00 01/28/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 676487241
Principal investigator 1 Gilead Sciences, Inc. $2,896.00 01/28/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma No dispute reported 06/30/2026 676487245
Principal investigator 1 Incyte Corporation $1,770.20 01/15/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666468985
Principal investigator 1 Incyte Corporation $424.00 01/15/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Open Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With AdvancedMetastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy No dispute reported 06/30/2026 666468987
Principal investigator 1 Gilead Sciences, Inc. $245.00 01/14/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors No dispute reported 06/30/2026 676487233
Principal investigator 1 Incyte Corporation $95.00 01/01/2019 Covered Recipient Teaching Hospital
PARKVIEW HOSPITAL
A Phase 2, Multicenter, International, Open Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B Cell Lymphoma No dispute reported 06/30/2026 666469707